ClinicalTrials.gg
CompletedNCT03861416Updated Jan 31, 2020

"Unifuzol®" in Patients With Peripheral Arterial Disease

A Phase 2 interventional study of L-arginine 1.4% 500 ml and L-arginine 1.4% 250 ml + placebo 250 ml in Peripheral Arterial Disease, sponsored by POLYSAN Scientific & Technological Pharmaceutical Company. Completed at 19 sites in Russian Federation. Open to participants aged 40 Years to 79 Years. Per ClinicalTrials.gov, last updated 2020-01-31.

Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2018, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
40 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Peripheral Arterial Disease with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Peripheral Arterial Disease · Russian Federation.

Enrollment
10th of 19
360 · median 360
Started
2018
with 3 others
Phase 2
3 of 21
none open now
Registered
14th of 21
by date

Among the 21 studies in Peripheral Arterial Disease with a site in Russian Federation, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 2, and was the 14th registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

2 of the 21 studies in Peripheral Arterial Disease with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 40 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Peripheral Arterial Disease with a site in Russian Federation, or all of them as a file.
02

Study summary

The present study is a multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of the drug Unifuzol® (L-arginine) in patients with obliterating atherosclerosis of the lower extremities. The study recruits patients 40-79 years old with a confirmed diagnosis of chronic ischemia of the lower limb and a stable symptom of intermittent claudication that occurs when walking a distance of 100-299 meters. L-arginine improves microcirculation due to activation of nitrogen monoxide production and stimulates capillary blood flow, thus can probably improve the quality of life of patients with intermittent claudication. The criterion for treatment efficacy will be an increase in the maximum walking distance measures before and on the next day after the end of treatment course.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Peripheral Arterial Disease
  • Arterial Occlusive Disease
  • intermittent claudication
04

Who can participate

Ages eligible
40 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Male and female patients 40-79 years old
  3. Patients with atherosclerosis of native arteries of the lower extremity vessels (ICD-10 code: I70.2)
  4. Clinical syndrome of chronic lower limb ischemia
  5. The symptom of intermittent claudication persisting for 6 months or more (before the start of screening), causing a stable restriction of physical activity to the maximum walking distance 100-299 m
  6. The ankle-brachial index (ABI) less than 0.9; in patients with diabetes mellitus ABI >1.2 is acceptable, provided the occlusion of the main arteries of the lower extremities is confirmed
  7. Patient consent to the use of adequate methods of or full abstinence from sexual activity for the period of the study and within 30 days after its completion
  8. The difference between the maximum walking distance at the second and the first treadmill test at the screening (interval at least 3 days) does not exceed 25% from baseline, i.e. the first treadmill test
  9. Patients not receiving drugs for the treatment of atherosclerosis obliterans of the lower extremities or receiving them in constant doses for at least 6 weeks prior to screening.
  10. No for treadmill test

Exclusion criteria

Exclusion Criteria:

  1. Intolerance or to the components of the study drug.
  2. Intake of succinic acid, L-arginine, malic acid, fumaric acid, anticoagulants, or hormones (with the exception of insulin) within 6 weeks before the start of screening, or the use of these medications is scheduled within the patient's participation in the study
  3. Any severe disease or condition that may make it unsafe and/or impossible for the patient to participate in the study and/or lead to the inability of the patient to comply with the study procedures (including, but not limited to: renal failure, hepatic failure, blood diseases, psychiatric conditions, infections)
  4. History of (with the exception of basal cell skin cancer)
  5. Alcohol or drug abuse
  6. The presence of decompensated cardiovascular diseases (unstable angina or stenocardia of functional class III and above, chronic heart failure III - IV class according to , uncontrolled arterial hypertension, acute cerebrovascular accident or acute myocardial infarction within 6 months prior to screening, unstable arrhythmias, deep venous thrombosis, stenosis of the internal carotid arteries >70%, aortic aneurysm)
  7. Decompensation of the peripheral circulation: rest pain, trophic ulcers, gangrene
  8. Any other diseases that affect the assessment of walking distance and limit patient's physical activity
  9. The level of (HbA1c) >= 8%
  10. Planned reconstructive surgery on the limb vessels within 6 months from screening
  11. Amputation on one or both limbs or planned amputation within 6 months from screening
  12. Other circumstances impeding patient compliance with the schedule of procedures
  13. For patients applying or planning the use of NSAIDs: the inability to cancel the use of NSAIDs 12 hours before the treadmill test.
  14. The >35
  15. for conducting the treadmill test
  16. Heart rate is more than 80% of the maximum frequency (the maximum frequency is defined as 220 - age) at the moment of pain in the legs.
  17. Depression of an ST segment or the occurrence of sustained (lasting more than 30 seconds) cardiac rhythm or conduction disturbances during a treadmill test.
  18. Drop of systolic blood pressure during the first 5 minutes after the completion of the treadmill test
  19. Participation in another clinical study
  20. Pregnancy or breastfeeding
  21. Any other diseases / conditions in the stage of decompensation
  22. Employees of the research center and their family members.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    Unifuzol® 1.4% 500 ml

    Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days

    Drug: L-arginine 1.4% 500 ml

  • Experimental
    Unifuzol® 1.4% 250 ml

    Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days

    Drug: L-arginine 1.4% 250 ml + placebo 250 ml

  • Placebo comparator
    Placebo 500 ml

    Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.

    Drug: Placebo solution

Interventions

  • Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days

    Also known as: Unifuzol® 1.4%

  • DrugL-arginine 1.4% 250 ml + placebo 250 ml

    Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.

    Also known as: Unifuzol® 1.4% 250 ml and placebo 250 ml

  • DrugPlacebo solution

    Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days

    Also known as: Ringer's solution

06

What researchers measure

Primary outcomes

  1. Maximum walking distance

    The change in the maximum walking distance on the next day (day 11) after the completion of treatment course and on day 30 in comparison with the initial value. The change will be expressed as the ratio of the natural logarithms of the maximum walking distance on day 11 and to the baseline value (day 1).

    Time frame: day 11, day 30

07

Study locations

19 sites
  • Regional Clinical Hospital
    Barnaul, Russian Federation
  • Kursk City Clinical Emergency Hospital
    Kursk, Russian Federation
  • City Clinical Hospital № 15 named O.M. Filatov
    Moscow, Russian Federation
  • Medical and sanitary Department of the Ministry of Internal Affairs of the Russian Federation in Moscow
    Moscow, Russian Federation
  • City Clinical Hospital №2 of the Novosibirsk Region
    Novosibirsk, Russian Federation
  • National Medical Research Center named after Academician E.N. Meshalkin
    Novosibirsk, Russian Federation
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, Russian Federation
  • Multidisciplinary center of modern medicine "Euromed"
    Omsk, Russian Federation
  • Orenburg Regional Clinical Hospital
    Orenburg, Russian Federation
  • Rostov State Medical University
    Rostov-on-Don, Russian Federation
  • Ryazan Regional Clinical Cardiological dispensary
    Ryazan, Russian Federation
  • City General Hospital №2
    Saint Petersburg, Russian Federation
  • City Hospital №38 named after N.A. Semashko
    Saint Petersburg, Russian Federation
  • Consultative and diagnostic center No. 85
    Saint Petersburg, Russian Federation
  • Road Clinical Hospital of the Russian Railways Open Joint-Stock Company
    Saint Petersburg, Russian Federation
  • St. Petersburg State Medical University n.a. I.P.Pavlov
    Saint Petersburg, Russian Federation
  • Regional Clinical Cardiology Dispensary
    Saratov, Russian Federation
  • Clinical hospital №10 of the Yaroslavl region
    Yaroslavl, Russian Federation
  • Regional Clinical Hospital of the Yaroslavl region
    Yaroslavl, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Sep 2019, 17 months.

Of 27 phase 2 interventional studies under Peripheral Arterial Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2019
First posted
Mar 4, 2019
StartActual
Mar 16, 2018
Primary completionActual
Sep 13, 2019
CompletionActual
Oct 26, 2019
Last update
Jan 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03861416
Responsible party
Sponsor
First posted
Mar 4, 2019
Start date
Mar 16, 2018
Primary completion
Sep 13, 2019
Completion
Oct 26, 2019
Last update
Jan 31, 2020

Study contacts

Mikhail S Bogomolov, MD, PhD
study director · St. Petersburg State Medical University n.a. I.P.Pavlov

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine

Start the discussion